News FDA makes history, approving Spark's eye gene therapy Christmas has come a few days early for Spark Therapeutics after the FDA approved its ground-breaking gene therapy for a rare eye disease.
Partner Content Partner Content Europe’s Leading Ophthalmic Conference is Just 1 week away Ophthalmic Drugs
Partner Content Partner Content SMi’s Europe’s Leading Ophthalmic Conference is only 2 weeks... Ophthalmic Drugs
News FDA approves Valeant eye drug after manufacturing delay Regulator backs potential blockbuster ophthalmology drug
Views & Analysis Learning from a successful ophthalmology brand launch Applying learnings from a successful ophthalmology brand launch to other therapy areas and pharmaceutical brands.
News GSK gets second cancer drug approval from Nuvalent buy The FDA has cleared GSK's ALK inhibitor Nelkarmi for a form of lung cancer, the second product from its $10.6bn acquisition of Nuvalent.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.